210 related articles for article (PubMed ID: 18316953)
21. Management of hypertriglyceridemia.
Oh RC; Lanier JB
Am Fam Physician; 2007 May; 75(9):1365-71. PubMed ID: 17508532
[TBL] [Abstract][Full Text] [Related]
22. Omega-3 fatty acids: antiarrhythmic, proarrhythmic or both?
von Schacky C
Curr Opin Clin Nutr Metab Care; 2008 Mar; 11(2):94-9. PubMed ID: 18301082
[TBL] [Abstract][Full Text] [Related]
23. Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia.
Ali YS; Linton MF; Fazio S
Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):142-6. PubMed ID: 18316949
[TBL] [Abstract][Full Text] [Related]
24. Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia.
Skulas-Ray AC; West SG; Davidson MH; Kris-Etherton PM
Expert Opin Pharmacother; 2008 May; 9(7):1237-48. PubMed ID: 18422480
[TBL] [Abstract][Full Text] [Related]
25. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins?
Goumas GS
Angiology; 2009; 60(1):93-8. PubMed ID: 19019838
[TBL] [Abstract][Full Text] [Related]
26. Treatment of HIV-associated dyslipidemia: a role for omega-3 fatty acids.
Metroka CE; Truong P; Gotto AM
AIDS Read; 2007 Jul; 17(7):362-4, 367-73. PubMed ID: 17672015
[TBL] [Abstract][Full Text] [Related]
27. Omega-3 fatty acids in major depressive disorder.
Freeman MP
J Clin Psychiatry; 2009; 70 Suppl 5():7-11. PubMed ID: 19909687
[TBL] [Abstract][Full Text] [Related]
28. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
[TBL] [Abstract][Full Text] [Related]
29. The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study.
Svensson M; Schmidt EB; Jørgensen KA; Christensen JH
Nephrol Dial Transplant; 2008 Sep; 23(9):2918-24. PubMed ID: 18436564
[TBL] [Abstract][Full Text] [Related]
30. Fish oil: what is the role in cardiovascular health?
Brinson BE; Miller S
J Pharm Pract; 2012 Feb; 25(1):69-74. PubMed ID: 21676848
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
Maciejewski S; Hilleman D
Pharmacotherapy; 2008 May; 28(5):570-5. PubMed ID: 18447655
[TBL] [Abstract][Full Text] [Related]
32. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids.
Robinson JG; Stone NJ
Am J Cardiol; 2006 Aug; 98(4A):39i-49i. PubMed ID: 16919516
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy in the management of mixed dyslipidaemia.
Cannon CP
J Intern Med; 2008 Apr; 263(4):353-65. PubMed ID: 18324928
[TBL] [Abstract][Full Text] [Related]
34. Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia.
Rupp H
Adv Ther; 2009 Jul; 26(7):675-90. PubMed ID: 19629408
[TBL] [Abstract][Full Text] [Related]
35. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids.
Bays H
Am J Cardiol; 2006 Aug; 98(4A):71i-76i. PubMed ID: 16919519
[TBL] [Abstract][Full Text] [Related]
36. Antiarrhythmic effects of omega-3 fatty acids.
Reiffel JA; McDonald A
Am J Cardiol; 2006 Aug; 98(4A):50i-60i. PubMed ID: 16919517
[TBL] [Abstract][Full Text] [Related]
37. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
[TBL] [Abstract][Full Text] [Related]
38. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
Adiels M; Olofsson SO; Taskinen MR; Borén J
Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1225-36. PubMed ID: 18565848
[TBL] [Abstract][Full Text] [Related]
39. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
40. Fatty acid facts, Part III: Cardiovascular disease, or, a fish diet is not fishy.
Pauwels EK; Kostkiewicz M
Drug News Perspect; 2008 Dec; 21(10):552-61. PubMed ID: 19221636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
